Neurocrine Biosciences, Inc. (NBIX) Stock Overview
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with…
Source: Yahoo Finance
Sector & Industry
Neurocrine Biosciences, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry group. It is listed on the NASDAQ exchange.
Neurocrine Biosciences, Inc. at a Glance
| Company | Neurocrine Biosciences, Inc. |
| Ticker | NBIX |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $155.64 |
| Market cap | $15.82B |
| P/E ratio (trailing) | 22.79 |
| EPS (trailing) | $6.83 |
| 52-week high | $186.12 |
| 52-week low | $122.14 |
| Dividend yield | — |
| Ex-dividend date (last paid) | 29 Dec 1995 |
| Beta | 0.38 |
| Return on equity (ROE) | 22.09% |
| Debt-to-equity | 12.50% |
| Average volume | 1.23M |
| Shares outstanding | 101.65M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 2,500 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Frequently Asked Questions
- What is Neurocrine Biosciences, Inc.'s current P/E ratio?
- Neurocrine Biosciences, Inc. (NBIX) has a trailing P/E ratio of 22.79 as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Neurocrine Biosciences, Inc.'s market capitalisation?
- Neurocrine Biosciences, Inc.'s market cap is $15.82B based on our latest snapshot. See how it ranks by market cap →
- What is NBIX's 52-week range?
- Over the past 52 weeks, NBIX has traded between $122.14 and $186.12. What does the 52-week range mean? →
- How volatile is Neurocrine Biosciences, Inc. compared to the market?
- Neurocrine Biosciences, Inc. has a beta of 0.38, meaning it has historically moved less than the broader market. What does beta measure? →
- Does Neurocrine Biosciences, Inc. pay a dividend?
- Neurocrine Biosciences, Inc. does not currently pay a dividend according to our latest data.
- What exchange is NBIX listed on?
- NBIX is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Neurocrine Biosciences, Inc. in?
- Neurocrine Biosciences, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Prefer raw numbers at a glance? Browse our size and reference charts for quick lookups.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Philip Fisher on what makes a business worth owning for the long term.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →